minimal residual disease

AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...

KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...

CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...

SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...

SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...

SECAUCUS, N.J., June 24, 2026 Quest Diagnostics announced that the New York State Department of Health’s Clinical Laboratory Evaluation...

IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...

LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...

BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...

Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...